Acute Coronary Syndrome: What Is Safer, Antiaggregant Monotherapy or De-Escalation?

For several years it has been shown that 12-month dual antiplatelet therapy (DAPT) is mandatory for patients undergoing left main PCI for acute coronary syndrome (ACS). However, though this strategy does reduce thrombotic events and mortality, it also causes undesirable bleeding events followed by hospitalization and antiaggregation interruption for a period of time. 

Síndromes coronarios agudos: ¿Qué es más seguro: monoterapia con antiagregante o De-Escalation?

A feasible strategy could be to interrupt one of the antiaggregants (be it aspirin -ASA- or P2Y12 inhibitor). The alternative could be to switch (De-Escalation) to a P2Y12 inhibitor of lower antiaggregation power (for example from prasugrel or ticagrelor to clopidogrel) or to reduce dosage.

This question remains unanswered.

This meta-analysis included 29 studies with 50602 patients, and it compared short duration antiaggregation (SHORT DAPT) vs. de-escalation.

Mean age was 63, there was an important number of women and a percentage of diabetics that ranged between 22% and 26%. There were no differences in all-cause mortality. 

De-escalation reduced the risk of net adverse cardiovascular events (NACE) (RR: 0.87; 95% CI: 0.70-0.94) but increased the risk of major bleeding (RR: 1.54; 95% CI: 1.07-2.21).

Read also: IVUS in Acute Coronary Syndrome: A New Requirement?

De-Escalation showed >95% probability to prevent NACE, MI, stroke, stent-thrombosis, and minor bleeding. However, it showed a very high rate of major bleeding. 

On the other hand, the SHORT DAPT approach showed better performance (>95%) in the prevention of major bleeding.

Conclusion

In patients with acute coronary syndrome undergoing PCI there were no differences in all-cause mortality between SHORT DAPT and De-Escalation. De-Escalation reduced NACE risk, while SHORT DAPT reduced the risk of major bleeding. 

These data characterize 2 contemporary strategies to personalize the use of DAPT according to treatment goals and risk profile.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the SOLACI.org Editorial Board. 

Original Title: Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.

Reference: Claudio Laudani, et al. J Am Coll Cardiol Intv 2022;15:268–277.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...